Results 231 to 240 of about 294,471 (310)
Role of Mast Cells in Human Health and Disease: Controversies and Novel Therapies. [PDF]
Galván-Morales MÁ +3 more
europepmc +1 more source
This study presents a post hoc analysis of longitudinal changes in peanut component‐specific IgE and IgG4 in children aged 1–4 years undergoing peanut SLIT, aiming to uncover immune mechanisms and potential biomarkers of remission. Peanut SLIT reduced IgE and increased IgG4 responses to Ara h 1, Ara h 2, Ara h 3, and Ara h 6.
Neel Singh +9 more
wiley +1 more source
Unravelling the Intricate Link: Mast Cells and Estrogen-Induced Pain Sensitization in Endometriosis. [PDF]
Wang J, Mao X, Zhu L, Zhang X.
europepmc +1 more source
This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients.
P. E. Vonk +13 more
wiley +1 more source
Mast Cells and Interstitial Cystitis/Bladder Pain Syndrome Revisited. [PDF]
Ruetten H +6 more
europepmc +1 more source
Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen‐Specific Immune Responses
We used PBMC transcriptome from 50 hen's egg‐allergic patients to study the role of lncRNA in OIT. Positive correlation was found between 17 lncRNAs and the IL‐4/IL‐13 pathway in vivo, and the expression of the selected lncRNA aligned with CXCL8 upon PBMC egg‐restimulation.
Olivia Liong +5 more
wiley +1 more source
Mast cells are essential in the development of exposure-associated exercise-induced bronchoconstriction in a mouse model. [PDF]
Marain NF +7 more
europepmc +1 more source
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau +22 more
wiley +1 more source
MRGPRX2-expressing mast cells are increased in the GI tract of individuals with active inflammatory bowel disease and hereditary α-tryptasemia. [PDF]
Galeas-Pena M +13 more
europepmc +1 more source

